Parabilis Medicines, Inc. filed a Form 8-K on September 15, 2026, disclosing that the company intends to present updated clinical data from its ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients at the ESMO Congress 2026 in Madrid, Spain.

Key Highlights

  • Presentation date: Saturday, October 24, during a sarcoma-focused Proffered Paper session at ESMO Congress 2026 in Madrid, Spain.
  • Session time: The presentation is scheduled to begin at 2:45pm CEST (8:45am ET).
  • Drug and indication: Updated clinical data from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients will be presented.
  • Presentation format: The data will be delivered as an oral presentation in a Proffered Paper session.
  • Filing signatory: The report was signed by Thomas Kotarakos, Chief Financial Officer of Parabilis Medicines, Inc.

Parabilis Medicines Schedules ESMO Oral Presentation for Zolucatetide Desmoid Tumor Data

Parabilis Medicines, Inc. (NASDAQ:PBLS), a Delaware-incorporated biopharmaceutical company headquartered in Cambridge, Massachusetts, filed a current report on September 15, 2026 under Item 7.01 (Regulation FD Disclosure). According to the filing, the company is updating its guidance to reflect its intention to present updated clinical data from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients at the European Society for Medical Oncology (ESMO) Congress 2026.

The filing states the presentation will take place in Madrid, Spain, on Saturday, October 24, during a sarcoma-focused Proffered Paper session beginning at 2:45pm CEST (8:45am ET). The disclosure was made as an oral presentation format in that session. The company described the filing as furnished, not filed, under Regulation FD, and noted it "shall not be deemed 'filed' for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section."

Parabilis Medicines identifies itself as an emerging growth company as defined under applicable SEC rules, and has not elected to use the extended transition period for complying with new or revised financial accounting standards. The report was signed on behalf of the registrant by Thomas Kotarakos in his capacity as Chief Financial Officer.

What Was Disclosed

Parabilis Medicines disclosed via a Regulation FD filing its plan to present updated Phase 1/2 clinical data for zolucatetide in desmoid tumor patients at ESMO Congress 2026 in Madrid on October 24, in an oral Proffered Paper session starting at 2:45pm CEST.